全文获取类型
收费全文 | 31903篇 |
免费 | 2166篇 |
国内免费 | 443篇 |
专业分类
耳鼻咽喉 | 476篇 |
儿科学 | 409篇 |
妇产科学 | 383篇 |
基础医学 | 5215篇 |
口腔科学 | 566篇 |
临床医学 | 2791篇 |
内科学 | 6325篇 |
皮肤病学 | 1102篇 |
神经病学 | 2570篇 |
特种医学 | 2335篇 |
外科学 | 3976篇 |
综合类 | 187篇 |
一般理论 | 16篇 |
预防医学 | 1329篇 |
眼科学 | 728篇 |
药学 | 3197篇 |
中国医学 | 469篇 |
肿瘤学 | 2438篇 |
出版年
2024年 | 19篇 |
2023年 | 266篇 |
2022年 | 821篇 |
2021年 | 1225篇 |
2020年 | 603篇 |
2019年 | 935篇 |
2018年 | 1162篇 |
2017年 | 909篇 |
2016年 | 1307篇 |
2015年 | 1739篇 |
2014年 | 2012篇 |
2013年 | 2189篇 |
2012年 | 3112篇 |
2011年 | 3090篇 |
2010年 | 1925篇 |
2009年 | 1489篇 |
2008年 | 1978篇 |
2007年 | 1899篇 |
2006年 | 1670篇 |
2005年 | 1516篇 |
2004年 | 1270篇 |
2003年 | 992篇 |
2002年 | 870篇 |
2001年 | 283篇 |
2000年 | 234篇 |
1999年 | 162篇 |
1998年 | 118篇 |
1997年 | 92篇 |
1996年 | 72篇 |
1995年 | 54篇 |
1994年 | 45篇 |
1993年 | 41篇 |
1992年 | 56篇 |
1991年 | 61篇 |
1990年 | 37篇 |
1989年 | 23篇 |
1988年 | 25篇 |
1987年 | 18篇 |
1986年 | 36篇 |
1985年 | 14篇 |
1984年 | 9篇 |
1983年 | 24篇 |
1982年 | 20篇 |
1981年 | 10篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1977年 | 6篇 |
1972年 | 9篇 |
1971年 | 10篇 |
1969年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Moderate sedatives have been increasingly used to improve patient comfort during flexible bronchoscopy (FB). However, routine use of moderate sedation during FB is controversial because its efficacy and safety are not well established.This study aims to evaluate the efficacy and safety of moderate sedation during FB.A search was made of Medline, EMBASE, and the Cochrane Library to May 2014.Randomized controlled trials (RCTs) and quasi-RCTs were included.The main analysis was designed to examine the efficacy of moderate sedation during FB in sedation than no-sedation.The willingness to repeat FB was significantly more in sedation than no-sedation (odds ratio [OR] 2.30; 95% confidence interval [CI] 1.11–4.73; P = 0.02; I2 = 22.5). The duration of FB was shorter in sedation group than no-sedation group (standardized mean difference [SMD] −0.21; 95% CI −0.38 to −0.03; P = 0.02; I2 = 78.3%). Event of hypoxia was not significantly different between sedation and no-sedation groups (OR 0.86; 95% CI 0.42–1.73; P = 0.67; I2 = 0%). The SpO2 during procedure was not different between sedation and no-sedation groups (SMD −0.14; 95% CI −0.37 to 0.08; P = 0.21; I2 = 49.9%). However, in subgroup analysis without supplemental oxygen, the SpO2 was significantly lower in sedation than no-sedation group (SMD −0.45; 95% CI −0.78 to −0.11; P = 0.01; I2 = 0.0%).According to this meta-analysis, moderate sedation in FB would be useful in patients who will require repeated bronchoscopies as well as safe in respiratory depression. To our knowledge, although the various sedative drugs are already used in the real field, this analysis was the first attempt to quantify objective results. We anticipate more definite and studies designed to elucidate standardized outcomes for moderate sedation in FB. 相似文献
4.
Kun‐Yong Sung Seungkoo Lee Yeonjin Jeong Sang‐Yeul Lee 《The Australasian journal of dermatology》2021,62(1):60-63
A classic pilomatricoma, which usually presents with an asymptomatic, solitary, firm, subcutaneous nodule in the head, neck, or extremities of the paediatric population, is easily diagnosed based on its characteristic clinical and histopathological features. However, its variants often pose particular diagnostic challenges to clinicians due to their rarity and diverse clinicopathological features. We present a new pseudocystic variant, manifesting as solid lesions floating in a fluid‐filled sac. 相似文献
5.
Paul Tetteh Asare Nadeeka Bandara Tae-Yong Jeong Sangryeol Ryu Jochen Klumpp Kwang-Pyo Kim 《Archives of virology》2015,160(10):2647-2650
6.
M.‐Q. Man L. Ye L. Hu S. Jeong P. M. Elias C. Lv 《Clinical and experimental dermatology》2019,44(6):654-657
While therapeutic approaches for psoriasis are widely available, preventive regimens are lacking. We aimed to determine whether improvements in epidermal function could prevent psoriasis relapse. Two self‐controlled cohort studies were designed, enrolling two cohorts of patients with psoriasis (n = 30 and n = 60) to be treated topically with an in‐house‐prepared emollient or ATOPALM® cream applied twice daily to one forearm for 20 and 30 days, respectively, while the same sites on the contralateral arm served as the untreated control. Epidermal function on both arms was assessed prior to and at the end of the trials. Delayed relapse on the treated arm was seen in 54.5% and 71% of patients in the first and second cohort, respectively. The time of psoriatic relapse correlated with the extent of abnormalities in baseline epidermal function. These results suggest that improvements in epidermal function with topical emollients can prevent/attenuate the development of psoriasis. 相似文献
7.
Jae Hwang Song Chan Kang Deuk Soo Hwang Dong Hun Kang Yong Hwan Kim 《Foot and Ankle Surgery》2019,25(6):748-754
BackgroundThe purpose of this study was to investigate and compare the clinical outcomes of dorsal suspension with those of neurectomy for the treatment of Morton’s neuroma.MethodsWe conducted a retrospective study of dorsal suspension and neurectomy group. The dorsal suspension was performed by dorsal transposition of neuroma over the dorsal transverse ligament after neurolysis. The visual analog scale (VAS), the Foot and Ankle Ability Measure (FAAM), postoperative satisfaction, and complications were evaluated.ResultsBoth groups reported significant pain relief, and there were no significant differences between the groups with respect to postoperative pain. The postoperative FAAM outcomes showed no significant between-group differences. Satisfaction analysis showed ‘excellent’ and ‘good’ results in the dorsal suspension and neurectomy groups (95% and 77.7%, respectively). Complications of numbness and paresthesia reported in the dorsal suspension group (5% and 5%, respectively) were significantly fewer than those of neurectomy group (61.1% and 33.3%, respectively) (both, p < .05).ConclusionsWith its favorable results, dorsal suspension can be another operative option for the treatment of Morton’s neuroma.Level of Evidence: Level III, retrospective comparative case series. 相似文献
8.
9.
10.
Catherine L. Omosule Dominique Joseph Brooke Weiler Victoria L. Gremminger Spencer Silvey Youngjae Jeong Ashique Rafique Pamela Krueger Sandra Kleiner Charlotte L. Phillips 《Journal of bone and mineral research》2022,37(5):938-953
Osteogenesis imperfecta (OI) is a collagen-related bone disorder characterized by fragile osteopenic bone and muscle weakness. We have previously shown that the soluble activin receptor type IIB decoy (sActRIIB) molecule increases muscle mass and improves bone strength in the mild to moderate G610C mouse model of OI. The sActRIIB molecule binds multiple transforming growth factor-β (TGF-β) ligands, including myostatin and activin A. Here, we investigate the musculoskeletal effects of inhibiting activin A alone, myostatin alone, or both myostatin and activin A in wild-type (Wt) and heterozygous G610C (+/G610C) mice using specific monoclonal antibodies. Male and female Wt and +/G610C mice were treated twice weekly with intraperitoneal injections of monoclonal control antibody (Ctrl-Ab, Regn1945), anti-activin A antibody (ActA-Ab, Regn2476), anti-myostatin antibody (Mstn-Ab, Regn647), or both ActA-Ab and Mstn-Ab (Combo, Regn2476, and Regn647) from 5 to 16 weeks of age. Prior to euthanasia, whole body composition, metabolism and muscle force generation assessments were performed. Post euthanasia, hindlimb muscles were evaluated for mass, and femurs were evaluated for changes in microarchitecture and biomechanical strength using micro–computed tomography (μCT) and three-point bend analyses. ActA-Ab treatment minimally impacted the +/G610C musculoskeleton, and was detrimental to bone strength in male +/G610C mice. Mstn-Ab treatment, as previously reported, resulted in substantial increases in hindlimb muscle weights and overall body weights in Wt and male +/G610C mice, but had minimal skeletal impact in +/G610C mice. Conversely, the Combo treatment outperformed ActA-Ab alone or Mstn-Ab alone, consistently increasing hindlimb muscle and body weights regardless of sex or genotype and improving bone microarchitecture and strength in both male and female +/G610C and Wt mice. Combinatorial inhibition of activin A and myostatin more potently increased muscle mass and bone microarchitecture and strength than either antibody alone, recapturing most of the observed benefits of sActRIIB treatment in +/G610C mice. © 2022 American Society for Bone and Mineral Research (ASBMR). 相似文献